Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 2/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420333 | 1.00 | MAP2K2 (0.35) | MAP2K2MAP2K1CES2CES1 | |
| SCHEMBL6420326 | 1.00 | MAP2K2 (0.35) | MAP2K2MAP2K1CES2CES1 | |
| SCHEMBL1043784 | 0.84 | CYP2D6 (0.38) | MAP2K2MAP2K1 | |
| SCHEMBL1043783 | 0.84 | CYP2D6 (0.38) | MAP2K2MAP2K1 | |
| SCHEMBL11956098 | 0.82 | MAP2K1 (0.37) | MAP2K2MAP2K1CES2CES1 | |
| SCHEMBL7055982 | 0.81 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL7055978 | 0.81 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL4173119 | 0.79 | CES2 (0.32) | MAP2K1CES2CES1 | |
| SCHEMBL4173114 | 0.79 | CES2 (0.32) | MAP2K1CES2CES1 | |
| SCHEMBL25373513 | 0.78 | CES2 (0.32) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359917-B1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6821969-B2 | FOR THERAPY AND PROPHYLAXIS OF HERPESVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-1359917-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1220858-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002064145-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1220858-A2 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6340680-B1 | AS ANTIVIRAL AGENTS, AGAINST VIRUSES OF HERPES FAMILY | PHARMACIA AND UPJOHN COMPANY | 2002-01-22 | — | — | US | disclosed |
| WO-2001025239-A2 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | DDX5, IRF3, ZC3HAV1 | MAP2K2 4613/4885MAP2K1 4605/4885CES2 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.